On 28th February 2018, the European Medicines Agency’s (EMA) Management Board met to further discuss the building approval process for EMA’s future premises in Amsterdam. It is crucial that the EMA is in working order in Amsterdam on 30th March 2019, when the United Kingdom (UK) withdraws from the European Union (EU).
At the meeting, which is being held in Lisbon, Portugal, the Management Board voted on the amended offer of the Dutch government in relation to the EMA’s new permanent premises in the business district Zuidas. The Board have endorsed the notification to the EU’s Budgetary Authority of EMA’s intention to move to the new building. The brand new, tailor-made permanent premises are expected to fully address EMA’s requirements and the Dutch Authorities have confirmed that the permanent building will be ready by 15th November 2019. Since the last meeting on 6th February 2018, progress has been made which has helped to clarify outstanding technical and financial issues linked to EMA’s permanent premises.
A requirement of the EMA’s financial regulation is the notification to the EU’s Budgetary Authority of EMA’s intention to move to a new headquarters. The EMA can “only enter into a contractual obligation for its new final premises following a positive opinion from these bodies.” Once the EMA has notified the Budgetary Authority, it is expected that an opinion will be provided within four weeks.
To read more about the building approval process for the EMA premises in Amsterdam, please click here.